Back to Stocks

CBLL

Ceribell, Inc.
2 filings tracked
healthcaremedical devicesSMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

CeriBell is rapidly establishing itself as a dominant force in acute neurological monitoring, evidenced by a robust 29% year-over-year revenue increase to $26.5 million in the first quarter of 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the top-line growth, CeriBell's financial health is marred by a deepening deficit and accelerating cash burn. The company reported a net loss of $19.7 million for the quarter, and its accumulated deficit has climbed to $240.1 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CBLL filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a classic high-growth, high-risk biotech profile. CeriBell is successfully proving the demand for its AI-driven EEG platform, achieving impressive revenue growth and maintaining elite gross margins. However, the path to profitability remains obscured by an escalating operating loss and a heavy reliance on external financing and venture debt. The core tension for investors lies in whether the 29% growth rate can outpace the current cash burn before the 18-month runway expires. Ultimately, the company's valuation hinges on two binary outcomes: the successful commercialization of the LVO stroke monitor and the resolution of the Natus IP litigation. While the operational metrics suggest a product-market fit in the acute care setting, the financial statements reveal a company that is not yet operating with a sustainable cost structure. The next few quarters will be decisive in determining if CeriBell can transition its technological lead into a stable, cash-generative business.

Selected Quarter

Core Takeaway

CeriBell is successfully scaling its revenue and maintaining elite margins, but it is burning cash rapidly and facing significant legal headwinds that threaten its long-term runway.

Investor Lens

The trade-off is between an impressive top-line growth trajectory and a fragile balance sheet with a shrinking cash runway.

Watch Next

The outcome of the USITC investigation regarding Natus patent infringement and the FDA clearance status of the LVO stroke monitor.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.20Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 11

Net loss widened to $19.7 million, a 54% increase over the prior year period.

earnings miss
70%
bullishMay 11

Maintained an elite gross margin of 87% despite scaling operations.

margin expansion
90%
bullishMay 11

Received FDA Breakthrough Device Designation for LVO stroke monitoring system.

regulatory action
60%
neutralMay 11

Carrying $20 million in term loans at an effective interest rate of 9.5%.

debt restructure
40%
bearishMay 11

Net loss widened to $19.7 million, a 54% increase over the prior year period.

earnings miss
70%
bullishMay 11

Maintained an elite gross margin of 87% despite scaling operations.

margin expansion
90%
bullishMay 11

Received FDA Breakthrough Device Designation for LVO stroke monitoring system.

regulatory action
60%
neutralMay 11

Carrying $20 million in term loans at an effective interest rate of 9.5%.

debt restructure
40%

Filing History

10-QMay 11, 2026
Expand Sequence

The Q1 2026 filing presents a classic high-growth, high-risk biotech profile. CeriBell is successfully proving the demand for its AI-driven EEG platform, achieving impressive revenue growth and maintaining elite gross margins. However, the path to profitability remains obscured by an escalating operating loss and a heavy reliance on external financing and venture debt. The core tension for investors lies in whether the 29% growth rate can outpace the current cash burn before the 18-month runway expires. Ultimately, the company's valuation hinges on two binary outcomes: the successful commercialization of the LVO stroke monitor and the resolution of the Natus IP litigation. While the operational metrics suggest a product-market fit in the acute care setting, the financial statements reveal a company that is not yet operating with a sustainable cost structure. The next few quarters will be decisive in determining if CeriBell can transition its technological lead into a stable, cash-generative business.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.